Kornimate/medical-research-clean huggingface dataset:
viekira pak or mavyret treatment for patient with chronic kidney disease and hepatitis c

Conditions: Chronic Kidney Disease; Chronic Hepatitis C

Summary: open-label experimental trial of 12 weeks of viekira pak treatment ± ribavirin or mavyret for adults with chronic kidney disease and hepatitis c.

the objective of this study is to evaluate the effect of paritaprevir/ritonavir, ombitasvir, dasabuvir (referred to as viekira pak) ± ribavirin or glecaprevir / pibrentasvir (referred to as mavyret) for adults with advanced ckd with an estimated glomerular filtration rate (egfr) less than 45ml/min that are infected with hepatitis c virus (hcv) genotype 1 and to determine the effect of treatment on traditional and novel markers of kidney function and cardiovascular disease risk in patients with advanced ckd. during the course of this prospective, single arm treatment trial, we will measure currently accepted markers of kidney function and novel biomarkers of ckd progression to determine if they improve with eradication of hcv.

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 year of age 2. hcv genotype 1 ≥ 1000 iu/ml 3. 6. estimated glomerular filtration rate 15-45ml/min/1.73m2 as estimated by ckd-epi equation exclusion criteria: 1. pregnant or lactating females 2. uncontrolled depression or psychiatric disease 3. history or presence of any form of cancer within 3 years of enrollment 4. experiencing life-threatening cryoglobulinemic vasculitis requiring initiation of rituximab, steroids or plasmapheresis. 5. uncontrolled cardiovascular or pulmonary disease 6. experiencing symptoms attributed to uremia 7. anticipated need to begin renal replacement therapy in the next 6 months 8. history of kidney transplant

Keywords: ckd hcv
association between tendon-related transcription factor and ultrasound images and shoulder function

Conditions: Rotator Cuff Tears; Rotator Cuff Tendinosis

Summary: the purpose of this project is to extract effusions and damaged tendons during tendon repair therapy in patients with tendon tears. then, we would analyze tendon-related transcription factors from histology and cytology, and compare changes in tendon with ultrasound images. helps to understand the mechanism of tendon lesions.

according to past studies, it is often observed that changes in extracellular matrix, growth factors, and cytokines in degenerative tendons, indicating that the tendon is constantly changing. this change will in turn produce a change in the morphology of the tendon tissue in the ultrasound image. however, there have been few studies in the past literature on the correlation between constant changes in tendon-specific transcription factors and characterization on clinical ultrasound images. therefore, the purpose of this project is to extract the effusion and damaged tendon while performing tendon repair therapy in patients with tendon tears, and to analyze the tendon-related transcription factors from histology and cytology to understand the changes in tendon homeostasis. at the same time, the interpretation of clinical ultrasound images was combined to establish the relationship between the biochemical factors of the cell tissues of chronic tendon lesions and the clinical ultrasound image. this study will help us to understand the mechanism of chronic tendinopathy.

Eligibility criteria:
inclusion criteria: * age older than 20 y * shoulder pain more than 3 months and visual analogue scale (vas) \>4 * shoulder tendon defect on ultrasound images exclusion criteria: * diagnosis of cervical radiculopathy or other central or peripheral neuropathy * rheumatoid arthritis or other autoimmune diseases * have received any shoulder joint injection within three months * tumor or systematic inflammation

Keywords: ultrasonography rotator cuff tendinopathy
study on evaluating the effectiveness of statins in the treatment of moyamoya disease

Conditions: Moyamoya Disease

Summary: the purpose of this study is to investigate the effectiveness of statins in the treatment of moyamoya disease based on multimodal magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: 1. the imaging examination meets the diagnostic criteria for moyamoya disease; 2. sign the informed consent form; 3. age ≥18 years old; 4. baseline mrs score ≤2 points; 5. the patient receives revascularization/conservative treatment; 6. there is at least 1 imaging follow-up result. exclusion criteria: 1. patients with atherosclerosis, autoimmune diseases, meningitis, down syndrome, cranial trauma, or those who have undergone radioactive head irradiation, as these conditions may lead to secondary cerebrovascular disease and contribute to the development of moyamoya syndrome; 2. individuals under the age of 18; 3. participants who refuse to take part in this study; 4. pregnant patients; 5. those with concurrent intracranial aneurysms, cerebrovascular malformations, brain tumors, or hydrocephalus; 6. a history of stroke occurring more than three months prior to the diagnosis of moyamoya disease; 7. individuals with a history of coronary heart disease or previous cardiovascular and cerebrovascular surgical interventions, including cerebral revascularization, intracranial artery stent implantation, carotid artery stenting, endarterectomy, coronary artery bypass grafting, or coronary stent implantation; 8. allergies to contrast media; 9. patients with missing imaging data or whose image quality cannot be analyzed; 10. individuals who refuse or are unable to undergo imaging follow-up; 11. patients receiving other types of lipid-lowering drug treatments.
evaluation of clinical, morphologic and biochemical markers in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: by combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (ms) should be obtained

the current study aims to comprehensively investigate the individual clinical, morphological and biochemical aspects of ms in order to elucidate underlying mechanisms leading to disease progression. this shall ultimately serve to identify imaging and biochemical markers, which may support clinical management of persons with ms (pwms). the following markers will be assessed: demographics (age, sex), clinical (edss at baseline, disease duration); neuropsychological (sdmt (symbol digit modalities test) score); mri (magnetic resonance imaging) (lesion load, atrophy); biochemical markers analyzed in cerebrospinal fluid (csf), blood, dna, rna, peripheral blood mononuclear cells (pbmcs)

Eligibility criteria:
inclusion criteria: * patients with suspected or proven multiple sclerosis * the participants are patients who are in inpatient or outpatient care of the department of neurology at the medical university of graz, austria exclusion criteria: * excluded from the examinations are all patients for whom an mri examination is impossible or problematic

Keywords: biomarker progression mri cognition
transpulmonary pressure guided mechanical ventilation weaning in obesity

Conditions: Respiratory Failure; Obesity

Summary: this study will look at whether accounting for the amount of pressure generated by the chest wall and abdomen in a obese patient, using a measurement called transpulmonary pressure, can help shorten the amount of time patients spend on the ventilator. by decreasing the amount of time patients spend on the ventilator, they are less likely to develop complications such as infections, weakness or more procedures.

managing obese patients on the ventilator can be difficult due to the changes in their respiratory mechanics with little evidence as to best practices. this research will assess the utility of transpulmonary pressures in guiding mechanical ventilation in obese patients. this study with specifically look at whether using transpulmonary pressure guided positive end expiratory pressure (peep) titration for ventilation and spontaneous breathing trials (sbt) will shorten the time to liberation for obese patients on invasive mechanical ventilation for respiratory failure. the transpulmonary pressures will be calculated daily for all patients. patients will also be assessed daily for readiness for sbt. in the intervention group, subjects' peep will be titrated to achieve an end expiratory transpulmonary pressure of 0-2 cm h2o. this peep will be used for the sbt and clinicians will be encouraged to keep their patients on this peep after the sbt if they are not extubated. in the control group, patients will also be assessed daily for sbt readiness but will be managed with standard set pressures of 5 to 10 cm h2o of peep and 5 to 8 cm h2o of pressure above peep. the primary team can perform a t piece trial prior to extubation as clinically indicated.

Eligibility criteria:
inclusion criteria: * on invasive mechanical ventilation for respiratory failure for \< 48 hours * obese class ii or higher (bmi greater than or equal to 35.0 kg/m2) exclusion criteria: * contraindications to esophageal balloon catheter placement including esophageal, nasofacial, gastrointestinal abnormalities and platelets \<10,000/microliter * known pleural disease such as persistent pneumothorax, pleural effusion, or pleurodesis * neuromuscular disease * requires chronic mechanical ventilation prior to enrollment * severe neurologic injury * known difficult airway * life expectance is less than 48 hours

Keywords: transpulmonary pressure respiratory failure obesity invasive mechanical ventilation
identification of neuroprognostic factors for out-of-hospital cardiopulmonary arrest (mira29)

Conditions: Cardiac Arrest; Neurologic Dysfunction; Cognitive Impairment

Summary: from the informatized prehospital care registry, data will be collected anonymously for all patients' requiring cardiopulmonary resuscitation for an out-of-hospital cardiac arrest within the norther finistere sanitary region. first step of the model derivation will consist in multivariate analysis to extract the most pertinent variates associated with neurological outcome (evaluated using the cpc score); second step will consist in the use of artificial intelligence and machine-learning to derive the most discriminant score.


Eligibility criteria:
inclusion criteria: * cardiac arrest requiring cardiopulmonary resuscitation exclusion criteria: * death before cardiopulmonary resuscitation * pediatric patients
effect of in-place slow jogging on metabolic dysfunction-associated steatotic liver disease

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease

Summary: evaluating the effectiveness, safety, and feasibility of stationary ultra-slow running in treating masld patients.


Eligibility criteria:
inclusion criteria: 1. meeting the diagnostic criteria for masld. 2. aged between 18 and 70 years (inclusive), regardless of gender. 3. patients voluntarily participate in this clinical study, have signed the informed consent form, and agree to comply with all study requirements, including follow-up visits, examinations, and treatments. exclusion criteria: 1. exclusion of other conditions causing liver injury, including alcoholic hepatitis, active hepatitis b or c virus infection, drug-induced hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, wilson's disease, α1-antitrypsin deficiency, liver cancer (or family history of liver cancer), etc. 2. history of medication use for more than 2 weeks within the past year that may induce hepatic steatosis or steatohepatitis (e.g., amiodarone, methotrexate, systemic glucocorticoids, tetracycline, tamoxifen, estrogen exceeding hormone replacement doses, anabolic steroids, valproic acid, or other known hepatotoxins). 3. use of hepatoprotective drugs (including but not limited to reduced glutathione, glucurolactone, glycyrrhizin preparations, nicotinamide, bifendate, liver-protecting tablets, silymarin, polyene phosphatidylcholine, s-adenosylmethionine, ursodeoxycholic acid, vitamin e, or other herbal medicines affecting liver function) within 4 weeks prior to enrollment. 4. presence of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or history of liver transplantation at randomization or previously, or planned liver transplantation. 5. concurrent type 1 diabetes. 6. severe cardiovascular, cerebrovascular, renal, or hematopoietic system diseases, as well as mood disorders (e.g., anxiety, depression) or psychiatric illnesses. 7. patients with any type of malignancy or a history of malignancy. 8. hiv-positive status. 9. pregnant or breastfeeding women, or subjects of childbearing potential unwilling or unable to use effective contraception from the screening period until 6 months after discontinuation of the investigational drug. 10. participation in other interventional clinical trials within 12 weeks prior to screening. 11. patients with unstable weight (i.e., weight loss or gain exceeding 4 kg in the past 3 months) or those with conditions preventing participation in the exercise program. 12. other conditions deemed by the investigator as unsuitable for participation in this study.
study to evaluate efficacy, safety, tolerability and pharmacokinetics of azd1386 in patients with peripheral neuropathic pain

Conditions: Pain; Neuropathic Pain

Summary: the primary aim of this study is to investigate if azd1386 is efficacious as an analgesic in patients with peripheral neuropathic pain. this will be done by comparing the effect of azd1386 to placebo ("inactive substance") on pain.


Eligibility criteria:
inclusion criteria: * patients with painful symptoms due to neuropathic pain * provision of signed informed consent * non pregnant females exclusion criteria: * other pain conditions that may confound assessment of neuropathic pain, as judged by the investigator * history, and/or presence of somatic disease, which may interfere with the objectives of the study as judged by the investigator

Keywords: analgesic effect peripheral neuropathic pain posttraumatic neuralgia (ptn) postherpetic neuralgia (phn)
study of motexafin gadolinium for the treatment of non-hodgkin's lymphoma

Conditions: Lymphoma; Non-Hodgkin's Lymphoma

Summary: the primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-hodgkin's lymphoma (nhl). secondly, the safety and side effects of motexafin gadolinium will be evaluated.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * refractory or relapsed indolent nhl. eligible who histologies include follicular nhl (grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (malt) types * failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy * ecog performance status score either 0 or 1 * willing and able to provide written informed consent exclusion criteria: laboratory values of: * platelet count \< 50,000/µl * ast or alt \> 2 x the upper limit of normal (uln) * total bilirubin \> 2 x uln * creatinine \> 2.0 mg/dl and * greater than three prior regimens (where a regimen is defined as a treatment for nhl given after disease progression) * uncontrolled hypertension * known history of porphyria, g6pd deficiency, hiv

Keywords: lymphoma non-hodgkin's lymphoma indolent lymphoma relapsed lymphoma refractory lymphoma motexafin gadolinium
effects of freeze dried strawberry powder supplementation on vascular function and blood markers of cardiovascular risk

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to evaluate the effects of freeze dried strawberry powder on ldl cholesterol, central and peripheral blood pressure, indices of arterial stiffness, and other lipid and lipoprotein concentrations. the investigators hypothesize that the bioactive compounds in freeze dried strawberry powder may elicit beneficial effects on ldl cholesterol, as well as blood pressure and arterial health.

the proposed study design is a 3-period randomized crossover dose-response study to evaluate the effect of freeze dried strawberry powder supplementation on ldl-c and vascular health. research participants will be overweight or obese (bmi 25-39 kg/m\^2) but otherwise healthy adults with moderately elevated ldl-c (\>116 mg/dl or \>3.0mmol/l), blood pressure \<160/100 mmhg, total cholesterol below 273 mg/dl for men and below 284 mg/dl for women, and triglycerides below 350 mg/dl. subjects will be randomly assigned to three supplementation periods: 1) low dose freeze dried strawberry powder (13 g/d); 2) high dose freeze dried strawberry powder (40 g/d); and 3) a placebo powder. each powder will be provided for 4-6 weeks, separated by a 2-week washout period between treatment periods. baseline and endpoint testing will include blood collection and vascular testing.

Eligibility criteria:
inclusion criteria: 1. men and women 35-65 years of age 2. bmi ≥ 25 and ≤ 39 kg/m\^2 3. ldl-c \> 116 mg/dl 4. total cholesterol below 273 mg/dl for men and below 284 mg/dl for women 5. triglycerides below 350 mg/d 6. non-smokers 7. blood pressure \< 160/100 mmhg exclusion criteria: 1. history of acute or chronic inflammatory conditions or heart disease, kidney disease, liver disease, autoimmune disorders, or thyroid disease (unless controlled by medication and blood results within the previous 6 months are provided) 2. history of diabetes mellitus (and/or a fasting glucose \> 126 mg/dl at screening) 3. stage ii hypertension (blood pressure ≥ 160/100 mmhg) 4. lactation, pregnancy, or desire to become pregnant during the study 5. unwillingness to discontinue nutritional supplements, herbs, or vitamins, unless approved by investigator 6. use of medications/supplements for elevated lipids, blood pressure, or glucose 7. chronic use of non-steroidal anti-inflammatory or immunosuppressant medication 8. conditions requiring the use of steroids 9. unwillingness to refrain from blood donation prior to and during the study 10. any medical condition or abnormal laboratory value that is judged clinically significant by an investigator 11. allergy or sensitivity to strawberries or any ingredient in the study powders

Keywords: strawberry powder cardiovascular disease risk factors
tnf polymorphism and implantation rate

Conditions: Infertility

Summary: do tnf-308 and -238 polymorphisms impact the embryo implantation rate after in vitro fertilization (ivf) in women without female infertility factor ?

this study was performed in order to verify whether tnf-308 allele was associated with a higher implantation rate and multiple pregnancy rates in women without known infertility factors after ovarian hyperstimulation with exogenous fsh for ivf

Eligibility criteria:
inclusion criteria: * women * normal karyotype, * age under 38 years * serum follicle-stimulating hormone (day-3 fsh) levels below 10 ui/l exclusion criteria: * age under 18 years
systemic inflammation in liver cirrhosis

Conditions: Liver Cirrhosis

Summary: investigate systemic inflammation in liver cirrhosis patients


Eligibility criteria:
inclusion criteria: 1. decompensated liver cirrhosis, with endoscopy-verified high-risk esophagogastric varices; 2. adult patients aged 18-75 years; 3. willing to anticipate and informed consent form obtained exclusion criteria: 1. history of prior radio-interventional therapy (tips or brto), liver transplantation, splenectomy, or hepatectomy; 2. non-sinusoidal cirrhosis (e.g. vascular cirrhosis); 3. coexistence with advanced hepatocellular carcinoma or other malignancies; 4. coexistence with severe systemic diseases and less than 3 months of expected survival time; 5. acute infection within 4 weeks before recruitment; 6. antibiotic use within 4 weeks before recruitment; 7. initial antiviral therapy for hbv or hcv within 4 weeks before recruitment; 8. pregnant or lactating women; 9. patients resistant to long-term follow-up

Keywords: liver cirrhosis; systemic inflammation
return to work and living healthy after head and neck cancer

Conditions: Head and Neck Cancer

Summary: based on a randomized controlled trial, the manualized group intervention return to work and living healthy after head and neck cancer (reliance) for head and neck cancer survivors will be tested against a non-manualized control intervention (social counseling) in order to evaluate the efficacy of the reliance intervention compared to the control condition. the study design includes two phases, the initial study phase (pilot study) and the intervention study (rct). the aim of the pilot study is to implement and ensure the necessary standardized procedures for the implementation of patient recruitment and interventions. in the randomized controlled trial, potential participants are assigned to the intervention group or to the control group.


Eligibility criteria:
inclusion criteria: * diagnosis of laryngea, hypopharyngeal, oropharyngeal, tonsil or base of the tongue cancer within the last six months * curative treatment * completion of primary and follow-up treatment * fluency in german * written informed and voluntary consent * psychological distress (distress thermometer score \> 4) * self-perceived prognosis of employment (spe score ≥ 1) exclusion criteria: * alcohol dependency with physical withdrawal symptoms (cage score ≥ 3 and current use of alcohol) * acute suicidal tendencies * receiving old-age pension or will receive old-age pension within the next 12 months * cognitive impairment indicated in the medical records or by the attending doctor * being in psychotherapy
efficacy and safety of tenofovir disoproxil fumarate (tdf) 300mg in chinese subjects with chronic hepatitis b (chb)

Conditions: Hepatitis B

Summary: this is a multi-centre, double blind, double dummy, randomised, controlled study to evaluate the efficacy and safety of tdf 300mg qd versus adv 10mg qd in chinese subjects with chb. this study is designed to demonstrate the superiority of tdf 300mg qd over adv 10mg qd in treating chinese subjects with chb (hepatitis b e antigen \[hbeag\] positive subjects and hbeag negative subjects). it will also provide long-term efficacy and safety data (up to 240 weeks) for tdf 300 mg administered once daily.

this is a multi-centre, double-blind, double-dummy, randomised, controlled study to evaluate the efficacy and safety of tdf 300mg qd versus adv 10mg qd in chinese subjects with chb. four hundred and ninety-four subjects with chb (200 hbeag positive subjects and 294 hbeag negative subjects) will be randomised (1:1ratio) to either tdf 300mg qd or adv 10mg qd treatment arms. the primary endpoint is the proportion of subjects with blood hepatitis b virus (hbv) deoxyribonucleic acid (dna) \<400copies/ml (roche cobas taqman hbv test) at week 48 in hbeag positive subjects with chb and hbeag negative subjects with chb. this is a two-part study. the first treatment period (baseline to week 48) will investigate the effects of tdf and adv on safety and efficacy endpoints; dosing will be double-blind. this period will be followed by 192 weeks in which all subjects will receive open-label tdf (week 49 to week 240). subjects will undergo regular safety and efficacy assessments every 4 weeks for the first 12 weeks followed by every 12 weeks for a total of up to 5 years.

Eligibility criteria:
inclusion criteria: * hbeag positive/negative chb with blood hbvdna≥10\^5 copies/ml and elevated alt * nucleoside and nucleotide naïve chb subjects. previous lamivudine treatment is allowed in less than 10% of the total study population exclusion criteria: * subjects with hepatocellular carcinoma (hcc) potential or decompensated liver disease * subjects with acute liver disease due to other causes * subjects with medication history of immunosuppressive therapy, immunomodulatory therapy, systemic cytotoxic agents, chronic antiviral agents including chinese herbal medicines known to have activity against hbv (e.g., lamivudine, hepatitis b immunoglobulin (hbig)) within the previous 6 months prior to randomisation into this study

Keywords: tenofovir disoproxil fumarate chronic hepatitis b adefovir dipivoxil